The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

AC1O5TPK     (8S,11R,13S,14S,17R)-11-[4- [(Z)...

Synonyms:
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Asoprisnil

 

High impact information on Asoprisnil

 

Chemical compound and disease context of Asoprisnil

 

Biological context of Asoprisnil

 

Anatomical context of Asoprisnil

 

Gene context of Asoprisnil

  • Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy [2].
  • RESULTS: Treatment with 10(-7) M asoprisnil decreased EGF, IGF-I and TGFbeta3 mRNA and protein expression as well as p-EGFR, IGF-IRalpha and p-TGFbeta RII protein expression in leiomyoma cells cultured for 72 h [6].
  • OBJECTIVE AND METHODS: The present study evaluated the effects of asoprisnil on cell proliferation, the expression of apoptosis-related proteins, and apoptosis in cultured human uterine leiomyoma cells and matched normal myometrial cells [4].
  • Asoprisnil increased the TUNEL-positive rate, cleaved caspase-3, and cleaved poly(adenosine 5'-diphosphate-ribose) polymerase expression and decreased Bcl-2 protein expression in cultured leiomyoma cells [4].
  • Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata [3].

References

  1. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Chwalisz, K., Perez, M.C., Demanno, D., Winkel, C., Schubert, G., Elger, W. Endocr. Rev. (2005) [Pubmed]
  2. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. DeManno, D., Elger, W., Garg, R., Lee, R., Schneider, B., Hess-Stumpp, H., Schubert, G., Chwalisz, K. Steroids (2003) [Pubmed]
  3. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Chwalisz, K., DeManno, D., Garg, R., Larsen, L., Mattia-Goldberg, C., Stickler, T. Seminars in reproductive medicine. (2004) [Pubmed]
  4. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. Chen, W., Ohara, N., Wang, J., Xu, Q., Liu, J., Morikawa, A., Sasaki, H., Yoshida, S., Demanno, D.A., Chwalisz, K., Maruo, T. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  5. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Chwalisz, K., Elger, W., Stickler, T., Mattia-Goldberg, C., Larsen, L. Hum. Reprod. (2005) [Pubmed]
  6. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Wang, J., Ohara, N., Wang, Z., Chen, W., Morikawa, A., Sasaki, H., DeManno, D.A., Chwalisz, K., Maruo, T. Hum. Reprod. (2006) [Pubmed]
 
WikiGenes - Universities